Compare IRWD & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | MATV |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.7M | 494.1M |
| IPO Year | 2009 | 1996 |
| Metric | IRWD | MATV |
|---|---|---|
| Price | $4.44 | $9.64 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 460.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.24% |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $57.95 | $2.97 |
| Revenue Next Year | $4.39 | $4.20 |
| P/E Ratio | $28.87 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $0.55 | $4.45 |
| 52 Week High | $5.78 | $15.48 |
| Indicator | IRWD | MATV |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 58.26 |
| Support Level | $3.07 | $8.02 |
| Resistance Level | $5.67 | $11.54 |
| Average True Range (ATR) | 0.23 | 0.33 |
| MACD | 0.14 | 0.24 |
| Stochastic Oscillator | 95.52 | 85.14 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.